Cybin CEO to Discuss Medical Innovation at Milken Institute Global Conference

0.8 min readPublished On: May 5th, 2025By HCN News Team

LOS ANGELES- Cybin Inc. a neuropsychiatry company, announced that its Chief Executive Officer, Doug Drysdale, will participate in a panel discussion at the 28th Annual Milken Institute Global Conference. The panel, titled “The Global Landscape and Opportunities for Medical Breakthroughs,” is scheduled for May 5, 2025, at 2:30 p.m. PDT at the Beverly Hilton in Los Angeles.

The conference, running from May 4 to May 7, 2025, convenes leaders from various sectors to address pressing global challenges and explore innovative solutions. Cybin’s participation underscores its commitment to advancing mental healthcare through the development of novel treatment options.

Cybin is currently progressing its lead candidate, CYB003, a deuterated psilocin analog, into Phase 3 clinical trials for the adjunctive treatment of major depressive disorder. Additionally, the company is developing CYB004, a deuterated dimethyltryptamine (DMT) compound, in Phase 2 trials targeting generalized anxiety disorder.

The panel discussion will be accessible via a live webcast on Cybin’s investor relations website, providing stakeholders with insights into the company’s strategic direction and the broader landscape of medical innovation.

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.